Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.